Spero Therapeutics targets SP001 trial for 2027: Spero Therapeutics stock gains 3.85 percent
Published on 10/08/2026 at 15:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Spero Therapeutics (ISIN US84833T1034) targeted the start of a second-quarter 2027 phase II trial for SP001 in a September 27, 2026 conference presentation. Spero Therapeutics stock was trading at EUR 1.08 at Lang & Schwarz on October 8, 2026, up 3.85 percent from the prior close of EUR 1.04.
Three milestones shape the story
On July 14, 2026, Spero announced USD 105.0 million in royalty-backed financing, according to Investing.com. On August 12, 2026, the company reported an adjusted loss of USD 0.16 per share for the second quarter of 2026 versus USD 0.17 consensus, the same Investing.com page reported. On September 27, 2026, a Quartr conference summary said the planned SP001 trial would test two doses over six months.
What does SP001 change?
The program marks Spero's shift toward immunology and inflammation, while the company continues to develop treatments for serious diseases. The conference summary described SP001 as a third-generation, Fc-silent anti-CD40L antibody and said the cash runway extended into the second half of 2029, giving the planned trial a defined financing horizon.
Analyst expectations remain numerically wide. Fintel reported on October 2, 2026 that the average one-year target had risen 25.00 percent from USD 4.08 to USD 5.10, with individual targets ranging from USD 4.04 to USD 6.30. Those dollar targets are separate from the euro quotation for German-market investors.
Next dates for SPRO
Investing.com lists November 16, 2026 as Spero's next earnings date. The SP001 phase II start is targeted for the second quarter of 2027, according to Quartr.
Stock gains 3.85 percent in trading
Spero Therapeutics stock was trading at EUR 1.08 at Lang & Schwarz on October 8, 2026 at 3:02 p.m. CEST, plus 3.85 percent versus the prior close of EUR 1.04. The primary Nasdaq listing had a USD 1.08 to USD 3.08 52-week range and a USD 67.7 million market capitalization as of October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Spero Therapeutics stock.
Spero Therapeutics stock facts
- Company: Spero Therapeutics, Inc.
- ISIN: US84833T1034
- Ticker: SPRO
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 8, 2026, 3:02 p.m. CEST: EUR 1.08
- Change versus prior close: plus 3.85 percent
- Prior close Lang & Schwarz October 7, 2026: EUR 1.04
- Market capitalization: USD 67.7 million as of October 7, 2026
- 52-week range: USD 1.08-3.08 as of October 7, 2026
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 16, 2026
Market context: Market report Nasdaq Composite.
